We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is atai Life Sciences N.V. (ATAI - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
atai Life Sciences N.V. is one of 986 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. atai Life Sciences N.V. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ATAI's full-year earnings has moved 27.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ATAI has gained about 105.3% so far this year. Meanwhile, the Medical sector has returned an average of -2.6% on a year-to-date basis. This means that atai Life Sciences N.V. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Idexx Laboratories (IDXX - Free Report) . The stock is up 30.9% year-to-date.
For Idexx Laboratories, the consensus EPS estimate for the current year has increased 1.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, atai Life Sciences N.V. belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #23 in the Zacks Industry Rank. On average, stocks in this group have gained 2.1% this year, meaning that ATAI is performing better in terms of year-to-date returns.
In contrast, Idexx Laboratories falls under the Medical - Instruments industry. Currently, this industry has 84 stocks and is ranked #168. Since the beginning of the year, the industry has moved -8.2%.
Investors with an interest in Medical stocks should continue to track atai Life Sciences N.V. and Idexx Laboratories. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is atai Life Sciences N.V. (ATAI - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
atai Life Sciences N.V. is one of 986 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. atai Life Sciences N.V. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ATAI's full-year earnings has moved 27.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ATAI has gained about 105.3% so far this year. Meanwhile, the Medical sector has returned an average of -2.6% on a year-to-date basis. This means that atai Life Sciences N.V. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Idexx Laboratories (IDXX - Free Report) . The stock is up 30.9% year-to-date.
For Idexx Laboratories, the consensus EPS estimate for the current year has increased 1.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, atai Life Sciences N.V. belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #23 in the Zacks Industry Rank. On average, stocks in this group have gained 2.1% this year, meaning that ATAI is performing better in terms of year-to-date returns.
In contrast, Idexx Laboratories falls under the Medical - Instruments industry. Currently, this industry has 84 stocks and is ranked #168. Since the beginning of the year, the industry has moved -8.2%.
Investors with an interest in Medical stocks should continue to track atai Life Sciences N.V. and Idexx Laboratories. These stocks will be looking to continue their solid performance.